RKI-1447
≥98%
- Product Code: 230001
CAS:
1342278-01-6
| Molecular Weight: | 326.37 g./mol | Molecular Formula: | C₁₆H₁₄N₄O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
RKI-1447 is primarily used in biomedical research as a potent and selective inhibitor of Rho-associated coiled-coil containing protein kinase (ROCK). It is widely applied in studies related to cancer cell migration, invasion, and metastasis due to its ability to disrupt the Rho/ROCK signaling pathway, which plays a key role in cytoskeletal organization and cell motility. Researchers use RKI-1447 to investigate tumor progression in various cancer types, including breast, liver, and melanoma, where inhibition of ROCK activity leads to reduced cell contraction, altered adhesion, and suppression of invasive behavior.
In addition to oncology, RKI-1447 has been explored in studies involving cellular morphology and mechanotransduction. It helps modulate actin stress fiber formation and focal adhesion assembly, making it a valuable tool for understanding cell mechanics and signaling dynamics. Its application extends to ophthalmic research, particularly in models of glaucoma, where ROCK inhibitors are known to lower intraocular pressure by improving aqueous humor outflow. Despite its current role as a research compound, RKI-1447 holds potential for development into therapeutic agents targeting metastatic cancers and other diseases involving aberrant ROCK activity.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿3,350.00 |
+
-
|
| 0.050 | 10-20 days | ฿12,800.00 |
+
-
|
RKI-1447
RKI-1447 is primarily used in biomedical research as a potent and selective inhibitor of Rho-associated coiled-coil containing protein kinase (ROCK). It is widely applied in studies related to cancer cell migration, invasion, and metastasis due to its ability to disrupt the Rho/ROCK signaling pathway, which plays a key role in cytoskeletal organization and cell motility. Researchers use RKI-1447 to investigate tumor progression in various cancer types, including breast, liver, and melanoma, where inhibition of ROCK activity leads to reduced cell contraction, altered adhesion, and suppression of invasive behavior.
In addition to oncology, RKI-1447 has been explored in studies involving cellular morphology and mechanotransduction. It helps modulate actin stress fiber formation and focal adhesion assembly, making it a valuable tool for understanding cell mechanics and signaling dynamics. Its application extends to ophthalmic research, particularly in models of glaucoma, where ROCK inhibitors are known to lower intraocular pressure by improving aqueous humor outflow. Despite its current role as a research compound, RKI-1447 holds potential for development into therapeutic agents targeting metastatic cancers and other diseases involving aberrant ROCK activity.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :